ARTICLE | Company News
Vitae, Boehringer Ingelheim deal
October 5, 2009 7:00 AM UTC
Vitae received an $8 million payment from BI for an undisclosed performance milestone under a 2007 deal to develop and commercialize hydroxysteroid 11-beta dehydrogenase 1 (HSD11B1) (HSD1).inhibitors...